SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Value-based pricing for advanced therapy medicinal products: emerging affordability solutions
11 references·0 citing·44 second hop
Value-based pricing for advanced therapy medicinal products: emerging affordability solutions (2021)Value-based pricing for advanced therapy …A systematic review of economic evaluations of advanced therapy medicinal products (2020)A systematic review of econom…Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold (2019)Value-Based Pricing for Emerg…The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost (2019)The Landscape of Cellular and…Innovation and competition in advanced therapy medicinal products (2019)Innovation and competition in…Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures (2018)Affordability Challenges to V…Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare (2018)Advanced therapy medicinal pr…Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics (2017)Value-Based Pricing and Reimb…Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL) (2017)Recommendations from the Euro…Gene therapy: evidence, value and affordability in the US health care system (2017)Gene therapy: evidence, value…Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access (2017)Concise Review: The High Cost…Advanced therapy medicinal products: current and future perspectives (2016)Advanced therapy medicinal pr…Assessing the economic challenges posed by orphan drugs (2007)The High Cost of Cancer Drugs and What We Can Do About It (2012)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe (2018)Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy (2019)Why rare diseases are an important medical and social issue (2008)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development? (2018)Comparing access to orphan medicinal products in Europe (2019)Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut) (2019)Cost of Cancer Care: Issues and Implications (2007)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation (2016)Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions (2020)UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE (2003)Cost-Effectiveness in Health and Medicine (2016)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? (2022)Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options (2022)Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force (2013)Clinical development success rates for investigational drugs (2014)Measuring the Value of Prescription Drugs (2015)HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies (2020)Integrative Review of Managed Entry Agreements: Chances and Limitations (2020)Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement (2013)Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context (2013)Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage (2017)Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis (2020)Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies (2020)Industry-Specific Factors Impeding the Implementation of Value-Based Pricing (2021)Toward a More General Theory of Regulation (1976)Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)Evaluating patient-based outcome measures for use in clinical trials. (1998)Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries (2020)The Use of Innovative Payment Mechanisms for Gene Therapies in Europe and the USA (2021)Bioequivalence: The Regulatory Career of a Pharmaceutical Concept (2011)Biosimilar Cost Savings in the United States: Initial Experience and Future Potential (2017)Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? (2017)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2003)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? (2021)The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis (2022)
this work references cited by second hop

References

  • 2016Advanced therapy medicinal products: current and future perspectives171 cited
  • 2018Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare124 cited
  • 2017Gene therapy: evidence, value and affordability in the US health care system105 cited
  • 2017Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)103 cited
  • 2019Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold93 cited
  • 2017Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics84 cited
  • 2019The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost80 cited
  • 2018Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures65 cited
  • 2017Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access58 cited
  • 2019Innovation and competition in advanced therapy medicinal products58 cited
  • 2020A systematic review of economic evaluations of advanced therapy medicinal products57 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work